EFALIZUMAB (RAPTIVA) COMBINED WITH SIROLIMUS IN TYPE 1 DIABETIC ISLET ALLOGRAFT

EFALIZUMAB (RAPTIVA) 与西罗莫司联合用于 1 型糖尿病胰岛同种移植术

• 批准号: 7951730
• 负责人: Bernhard Josef Hering
• 金额: $ 1.35万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951730
• 关键词: Antibodies; Antithymoglobulin; Cell Adhesion Molecules; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Immunosuppressive Agents; Institution; Insulin-Dependent Diabetes Mellitus; Islets of Langerhans Transplantation; Maintenance; Raptiva; Research; Research Personnel; Resources; Sirolimus; Source; Treatment Protocols; United States National Institutes of Health; efalizumab; improved; islet allograft; novel; type I diabetic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project aims to improve the applicability of islet transplantation for treatment of type 1 diabetes by utilizing novel immunosuppressive regimens centered on the use of adhesion molecule blockade with an anti-LFA-1 antibody and sirolimus maintenance with Anti-Thymocyte globulin induction.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该项目旨在通过利用新型免疫抑制方案提高胰岛移植治疗 1 型糖尿病的适用性，该方案的重点是使用抗 LFA-1 抗体进行粘附分子阻断，并通过抗胸腺细胞球蛋白诱导维持西罗莫司。